Vinge has advised Samhällsbyggnadsbolaget i Norden AB (”SBB”) in connection with a directed share issue, whereby SBB receives proceeds of approximately MSEK 500.
Vinge advises Fastighets AB Trianon (publ) in connection with a directed share issue of approximately SEK 398 million through an accelerated book building procedure.
Vinge has advised Samhällsbyggnadsbolaget i Norden AB (”SBB”) in connection with the sale of properties for SEK 10 billion to a company co-owned by Kåpan with a focus on government infrastructure.
Vinge has advised VNV Global in connection with a directed share issue amounting to approximately SEK 1,191 million at a subscription price of SEK 123 per share.
Vinge has advised Norditek Group AB in connection with its listing on Nasdaq First North Growth Market. The first day of trading is 10 November 2021. In connection with the listing, an invitation to subscribe for shares for a subscription price of SEK 11 was implemented, which was significantly oversubscribed by approximately 4.5 times.
Vinge acts as lead advisor to EQT AB in connection with its acquisition of Life Sciences Partners, a leading European life sciences venture capital firm with approximately EUR 2.2 billion of assets under management
Vinge has advised Hexatronic Group AB (publ) in connection with a directed share issue whereby the company receives approximately SEK 550 million in gross issue proceeds.
Vinge has advised Tobii AB in connection with a directed share issue whereby the company receives approximately SEK 300 million in gross issue proceeds.
Vinge has advised Xspray Pharma, a pharmaceutical company with several product candidates in clinical development listed on Nasdaq Stockholm, in connection with a share issue whereby the company raises proceeds of approximately SEK 100 million.
Vinge has advised XVIVO Perfusion AB in connection with a directed new issue of shares to Swedish and international investors that contributed MSEK 250 to XVIVO.
Vinge has advised Smart Eye Aktiebolag in connection with a directed new issue of shares to Swedish and international investors that contributed MSEK 220 to Smart Eye.
Vinge has advised Biotage AB (publ), listed on Nasdaq Stockholm, in connection with its acquisition of ATDBio Limited based in Oxford and Southampton, UK, for a total purchase price of approx. 45 MGBP on a debt free and cash free basis (corresponding to approx. 534.4 MSEK) financed through a combination of a share issue of new ordinary Biotage shares, cash at hand and a revolving credit facility. The transaction closed in connection with the entering into of the share purchase agreement.
